New research finds that FDA could enhance public safety by employing new data-driven approaches to identify adverse effects of drugs faster and more reliably, which would improve the regulatory decision-making and oversight processes.
The European Commission (EC) has released extensive recommendations for sponsors covering best practices for the development, translation, and distribution of lay summaries of clinical trial information, intended both for trial […]
A new report on how trends in market growth for virtual clinical trials are expected to play out in the next five years indicates an anticipation for a compound annual […]
These are exciting times to be a member of the Association of Clinical Research Professionals (ACRP). Just as the challenge of Covid-19 inspired clinical trial practitioners to attain new heights […]
New research in JNCCN—Journal of the National Comprehensive Cancer Network finds that more than 80% of therapies tested in Phase III oncology trials did not achieve meaningful clinical benefit in […]